Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Tirppur C. R. Ramakrishnan"'
Autor:
Amit Saraf, Percival C. Gilvaz, Tirppur C. R. Ramakrishnan, R. N. Komal Kumar, Salvadeeswaran Meenakshi‐Sundaram, Santosh M. Sontakke, Anand Alurkar, Somasundaram Kumaravelu, Pamidimukkala Vijaya, Mangesh Udar, Deepak Arjundas, Soaham Desai, Mukesh Sharma, Suresh BV, Rithesh R. Nair, Sadique Pathan, Shripad S. Pujari, Sudhir Kumar, Keyur Machhavada, Jayantee Kalita, Usha K. Misra, Bhalchandra Vaidya, Leonid Churilov, Mark W. Parsons, Sanjay Singh
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 23 (2024)
Background Tenecteplase has been approved for acute ischemic stroke at a dose of 0.2 mg/kg by the Indian licensing authority. A registry to evaluate the safety of tenecteplase was mandated by the licensing authority. The research aim was to use the I
Externí odkaz:
https://doaj.org/article/409d1f73084941ce8f623c71c15d1031
Autor:
Indraneel Basu, Usha K. Misra, Deepak Namjoshi, Shankara Nellikunja, Kizhakkaniyakath Abdul Salam, Sai S Buddha, Vikram Sharma, R Srinivasa, Shirish D Deshpande, M. C. Kumar, Sunil K Narayan, Rustom S. Wadia, Pamidimukkala Vijaya, S Kumaravelu, Deepak S Laddhad, Palakkapparampil H A Majeed, Zubin Vaid, Shahid Barmare, Ch Murali, Konbappan Asokan, Vijaykumar Dhonge, Tirppur C R Ramakrishnan, Tenecteplase in Stroke Investigators, Methil Pradeep, Salvadeeswaran Meenakshi-Sundaram, Pandurang R Wattamwar, Balakrishnan Raghunath, K K Nirmal Raj, Jayantee Kalita
Publikováno v:
American Journal of Cardiovascular Drugs. 18:387-395
Tenecteplase (TNK-tPA) is a promising third-generation plasminogen activator, because of its greater fibrin specificity and longer half-life than alteplase. There is a paucity of studies on intravenous thrombolysis using TNK-tPA in developing countri